###### Key messages

What is the key question?
=========================

-   Does the new once-daily ICS/LABA combination FF/VI reduce the risk of severe asthma exacerbations compared with ICS alone?

What is the bottom line?
========================

-   This randomised double-blind comparative study in patients with asthma uncontrolled on ICS confirms that the combination of FF 100 μg plus VI 25 μg reduces the risk of severe exacerbations compared with FF 100 μg alone.

Why read on?
============

-   This study, which employed a unique event-driven design to ensure sufficient power to study exacerbation frequency and in which most patients received treatments for \>1 year, confirmed that FF/VI with its once-daily dosing regimen is more effective in reducing exacerbation risk in uncontrolled asthma than FF alone.

Introduction {#s1}
============

The addition of a long-acting β~2~ agonist (LABA) to an inhaled corticosteroid (ICS) is recommended for patients whose asthma is inadequately controlled on medium-dose ICS.[@R1] This has been shown to improve both pulmonary function and asthma control and to reduce the risk of exacerbations,[@R2] [@R3] and is the most effective and preferred option for patients requiring a step-up in asthma controller therapy, at least in adolescents and adults. However, although almost all studies have confirmed that the addition of a LABA reduces asthma exacerbations, controversy has arisen around data from a large-scale safety study[@R4] and meta-analyses[@R5] [@R6] suggesting that more severe and life-threatening asthma events and even deaths may be increased in patients receiving LABAs. A possible explanation for this apparent increase in risk is the failure of patients being treated with LABA to receive concurrent ICS treatment.[@R4] [@R7] Indeed, this has been supported by meta-analyses comparing ICS/LABA administered as concurrent treatment (rather than from separate inhalers) with ICS alone.[@R6] [@R8] Nonetheless, this concern has resulted in reassessment of the benefits and costs of combined treatment with LABA and ICS, whether as mono-components or in combination inhalers, and for studies to examine more closely rare severe life-threatening asthma exacerbations.[@R9] Thus, large prospective safety trials of currently marketed LABAs are underway internationally.

A new ICS/LABA combination currently being evaluated for use in asthma and chronic obstructive pulmonary disease contains fluticasone furoate (FF) and vilanterol (VI). FF is a novel ICS structurally distinct from fluticasone propionate (FP), with an ester derived from 2-furoic acid at the C-17α position that replaces the simpler propionate ester,[@R10] conferring both greater affinity for the GC receptor and longer retention in respiratory tissues than FP.[@R11] Once-daily FF has been shown to be effective in phase IIb trials,[@R12] and the FF dose used in this study was selected on the basis of data from these studies. VI is a once-daily inhaled LABA shown to produce prolonged bronchodilation for at least 24 h. Previous clinical studies of FF/VI delivered from a single inhaler, conducted in patients with chronic obstructive pulmonary disease and including higher dosages of FF than in the present study, have shown this combination to have an acceptable safety profile.[@R15] [@R16]

We report here the results of a large study, with exposure of \>1 year in most patients, examining the benefits and risks of FF 100 μg and VI 25 μg administered once daily in combination in patients with asthma uncontrolled on ICS or ICS/LABA and who were consequently at increased risk of asthma exacerbations. The primary endpoint was time to first severe asthma exacerbations, as defined by the European Respiratory Society/American Thoracic Society (ERS/ATS) Task Force.[@R17] Safety endpoints included asthma events leading to hospitalisation and intubation. Preliminary results have been presented in abstract form.[@R18]

Methods {#s2}
=======

Patients {#s2a}
--------

Patients aged ≥12 years were eligible if they had a history of asthma as defined by the National Institutes for Health[@R19] for ≥1 year prior to screening, were using ICS at a dose of ≥200 μg/day FP or equivalent or ICS/LABA at a dose of 200/100--500/100 μg FP/salmeterol or equivalent for ≥12 weeks prior to screening and at a stable dose for 4 weeks prior to screening and throughout the run-in period, and had ≥1 asthma exacerbation requiring systemic corticosteroids and/or hospital or emergency room visit in the previous year.

Eligible patients had a best prebronchodilator forced expiratory volume in 1 s (FEV~1~) of 50--90% predicted normal at screening, and could demonstrate ≥12% and ≥200 mL reversibility with inhaled salbutamol/albuterol. Patients' ICS therapy was discontinued at randomisation and replaced with study medication. At randomisation, patients were required to have a recorded use of albuterol/salbutamol and/or asthma symptoms on ≥3 of the last 7 consecutive days on their daily diary.

Study design and treatments {#s2b}
---------------------------

This phase III randomised, multicentre, double-blind, parallel-group study (HZA106837; ClinicalTrials.gov registration number NCT01086384) was conducted at 167 centres in 11 countries between 22 February 2010 and 15 September 2011. After a 2-week run-in period during which baseline safety evaluations and measures of asthma status were conducted, patients were randomised (1:1) to one of two treatments administered via the ELLIPTA dry powder inhaler (GlaxoSmithKline). FF/VI 100/25 μg (representing an emitted dose from the dry powder inhaler of 92 μg for FF and 22 μg for VI) or FF 100 μg were administered once daily in the evening for a required minimum of 24 weeks and up to 78 weeks. Patients replaced their current short-acting bronchodilator and used albuterol/salbutamol as-needed for symptoms.

Patients were randomised using an automated interactive telephone-based system (RAMOS; GlaxoSmithKline, UK) in accordance with a computer-generated schedule (RandAll; GlaxoSmithKline, UK). Following randomisation, patients were not permitted to use ICS other than study medication (see online supplementary appendix for a full list of permitted and prohibited medications).

An event-driven design was employed, meaning that the study was planned to finish after 330 'events' had occurred. An event was defined as a patient\'s first severe asthma exacerbation in the study. A severe asthma exacerbation was defined using the ERS/ATS Task Force recommendation as a deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days, or inpatient hospitalisation, or emergency department visit due to asthma requiring systemic corticosteroids.[@R17] A blinded independent adjudication committee ensured that all severe asthma exacerbations were captured as defined in the protocol. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the endpoint analysis.

One interim analysis was performed to evaluate the primary endpoint (ie, time to first severe asthma exacerbation) and to identify any potential treatment harm by reviewing the most frequent on-treatment adverse events and asthma-related mortality/morbidity (see online supplementary appendix).

Outcome measurements {#s2c}
--------------------

The primary endpoint was time to first severe asthma exacerbation. Secondary efficacy endpoints were rate of severe asthma exacerbations per patient per year and change from baseline at week 36 in evening trough FEV~1~. Other endpoints are listed in the online supplementary appendix.

Safety {#s2d}
------

Safety endpoints relating to severe asthma exacerbations included the number of hospitalisations, emergency department/urgent care visits, unscheduled healthcare provider visits and intubations for an asthma event. General safety and tolerability endpoints including vital signs were monitored (see online supplementary appendix).

Patients were withdrawn from the study if they experienced three on-treatment severe asthma exacerbations in any 6-month period or four throughout the treatment period.

Statistical analysis {#s2e}
--------------------

Three hundred and thirty events were required to provide 90% power to detect a 30% reduction in risk (HR 0.70) of severe asthma exacerbation at a two-sided significance level of 0.05. The total sample size of 2000 (1000 per treatment arm) was based on assumptions of 10% loss to follow-up, 20% of patients in the FF arm having ≥1 severe asthma exacerbations per year and a recruitment pattern as specified in the protocol.

The primary efficacy endpoint was analysed by Cox proportional hazards analysis (FF/VI vs FF) of time to first severe asthma exacerbation, incorporating terms for baseline FEV~1~, sex, age and region. A Cox proportional hazards analysis was performed to examine treatment interactions with these covariates. Statistical methods for the secondary and other efficacy endpoints and sensitivity analyses including the interim analysis of the primary efficacy endpoint are described in the online supplementary appendix. All efficacy and safety analyses were carried out in the intent-to-treat (ITT) population other than those specified as being carried out in the per protocol (PP) population (see online supplementary appendix). The decision to exclude a patient or some of a patient\'s data from the PP population was made prior to breaking the blinding.

Results {#s3}
=======

Of 2668 patients screened, 2020 were randomised and 2019 comprised the ITT population ([figure 1](#THORAXJNL2013203600F1){ref-type="fig"}). The PP population consisted of 1792 patients (89% of the ITT population): 903 received FF 100 μg and 889 received FF/VI 100/25 μg. Demographics and baseline characteristics were generally similar across the treatment groups in the ITT ([table 1](#THORAXJNL2013203600TB1){ref-type="table"} and online supplementary table E1) and PP populations. All patients were taking ICS at baseline and approximately 60% of patients were also receiving a LABA either as a separate inhaler or as part of an ICS/LABA combination product. Adolescents (age 12--17 years) comprised 14% of the ITT population.

###### 

Patient demographics and baseline characteristics, intent-to-treat population

                                                          FF 100 μg (N=1010)   FF/VI 100/25 μg (N=1009)   Total (N=2019)
  ------------------------------------------------------- -------------------- -------------------------- ----------------
  Age, years                                              42.3 (16.82)         41.1 (17.10)               41.7 (16.96)
  Female sex, n (%)                                       689 (68)             661 (66)                   1350 (67)
  Never smoked, n (%)                                     868 (86)             870 (86)                   1738 (86)
  Former smoker, n (%)                                    142 (14)             139 (14)                   281 (14)
  Number of exacerbations in last 12 months, n (%)                                                        
   0                                                      1 (\<1)              0                          1 (\<1)
   1                                                      599 (59)             553 (55)                   1152 (57)
   2                                                      229 (23)             252 (25)                   481 (24)
   3                                                      100 (10)             101 (10)                   201 (10)
   4                                                      37 (4)               57 (6)                     94 (5)
   \>4                                                    44 (4)               46 (5)                     90 (4)
  Duration of asthma, years                               15.8 (13.3)          15.3 (12.8)                15.5 (13.0)
  Screening prebronchodilator FEV~1~, L                   2.10 (0.61)          2.11 (0.61)                2.11 (0.61)
  Screening % predicted FEV~1~                            69.0 (10.41)         68.8 (10.62)               68.9 (10.52)
  Screening % reversibility FEV~1~                        24.3 (12.10)         24.4 (12.71)               24.4 (12.41)
  Screening absolute reversibility FEV~1~, mL             500.0 (260.25)       499.1 (265.44)             499.6 (262.79)
  Baseline ACQ-7 score                                    2.154 (0.7324)       2.169 (0.7514)             
  Percentage of patients using ICS or ICS/LABA on entry                                                   
   ICS only                                               397 (39)             402 (40)                   
   ICS/LABA                                               613 (61)             607 (60)                   

Values are mean (SD) unless otherwise stated.

ACQ, Asthma Control Questionnaire; FEV~1~, forced expiratory volume in 1 s; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting β~2~ agonist; VI, vilanterol.

![Patient disposition and reasons for withdrawal post-screening. \*One patient was not randomised but received FF 100 μg in error and one patient was randomised but did not receive treatment; these patients are not included in the ITT population. The patient who received FF 100 μg in error received 5 days of treatment and then was withdrawn. No safety issues were identified during this treatment period; FF, fluticasone furoate; ITT, intent-to-treat; SAE, severe adverse event; VI, vilanterol.](thoraxjnl-2013-203600f01){#THORAXJNL2013203600F1}

Due to the event-driven study design, the duration of exposure to study treatment was variable. A minimum duration of active treatment of 24 weeks was planned; only patients who were either withdrawn by the investigator or withdrew voluntarily had \<24 weeks of treatment. All patients who completed the planned double-blind treatment period were treated for ≥24 weeks and no patients were treated for longer than 78 weeks. The mean duration of treatment exposure (52.0--52.7 weeks) and the proportion of patients who received treatment for ≥52 weeks (56--58%) were similar between the groups (see online supplementary figure E1).

Primary efficacy and related endpoints {#s3a}
--------------------------------------

FF/VI significantly delayed the time to the first severe asthma exacerbation relative to FF ([table 2](#THORAXJNL2013203600TB2){ref-type="table"}, [figure 2](#THORAXJNL2013203600F2){ref-type="fig"}). The adjusted probability of experiencing a severe asthma exacerbation by 52 weeks was 15.9% (95% CI 13.5% to 18.2%) in the FF 100 μg group and 12.8% (95% CI 10.7% to 14.9%) in the FF/VI 100/25 μg group. The HR for FF/VI 100/25 μg vs FF 100 μg was 0.795 (95% CI 0.642 to 0.985, p=0.036, adjusted for the interim analysis), representing a 20% risk reduction. Analysis of the PP population provided similar results: HR (FF/VI vs FF) was 0.722 (95% CI 0.548 to 0.950), representing a 28% risk reduction (p=0.020). A total of 340 patients experienced ≥1 severe exacerbations; \>99% of the severe asthma exacerbations entered into the case report form were confirmed by the adjudication committee. The outcomes of subgroup analyses of treatment interactions with baseline FEV~1~, age, sex and region showed a statistically significant (p\<0.10) interaction between baseline FEV~1~ and treatment (see online [supplementary figure](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2013-203600/-/DC1) E2). Interactions between treatment and the remaining factors (age, sex and region) were not statistically significant.

###### 

Cox proportional hazards analysis of time to first severe asthma exacerbation, intent-to-treat population

                                                                         FF 100 μg (N=1010)    FF/VI 100/25 μg (N=1009)
  ---------------------------------------------------------------------- --------------------- --------------------------
  Adjusted % probability of a severe asthma exacerbation by 52 weeks\*   15.9 (13.5 to 18.2)   12.8 (10.7 to 14.9)
  FF/VI 100/25 μg vs FF 100 μg                                                                 
   HR†                                                                                         0.795 (0.642 to 0.985)
   p Value†                                                                                    0.036

Values are mean (95% CI) unless otherwise stated.

\*Cox proportional hazards model estimate at mean baseline FEV~1~, age and proportional coefficients for sex and region.

†Adjusted for the interim analysis.

FF, fluticasone furoate; HR, hazard ratio; VI, vilanterol.

![Cox proportional hazards model cumulative incidence curve for time to first severe asthma exacerbation, intent-to-treat population. FF, fluticasone furoate; VI, vilanterol.](thoraxjnl-2013-203600f02){#THORAXJNL2013203600F2}

The possibility of informative censoring was explored. The Kaplan--Meier curves for time to first severe asthma exacerbation or withdrawal due to lack of efficacy, investigator discretion or withdrawal of consent between the two treatment groups did not differ from those of the primary analysis (see online [supplementary figure](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2013-203600/-/DC1) E3).

Secondary and other efficacy endpoints {#s3b}
--------------------------------------

The rate of severe asthma exacerbations per patient per year was significantly lower in the FF/VI 100/25 μg group than in the FF 100 μg group (0.14 vs 0.19), a reduction in rate of 25% (95% CI 5% to 40%; p=0.014). The number of patients experiencing ≥1 on-treatment severe asthma exacerbation was also lower in the FF/VI group: 186 patients (18%) with FF (271 exacerbations in total) versus 154 patients (15%) with FF/VI (200 exacerbations in total). The mean duration of a severe asthma exacerbation was 11 days in both groups. Online supplementary figure E4 shows the number and duration of severe asthma exacerbations experienced by individual patients during the study.

Trough FEV~1~ increased over the treatment period in both the FF and FF/VI treatment groups ([figure 3](#THORAXJNL2013203600F3){ref-type="fig"} and online [supplementary figure](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2013-203600/-/DC1) E5). FF/VI demonstrated statistically significant improvements over FF in trough FEV~1~, with adjusted mean changes of 83--95 mL (p\<0.001).

![Adjusted mean changes from baseline in trough forced expiratory volume in 1 s (L), intent-to-treat population. \*Treatment differences p\<0.001. FF, fluticasone furoate; LS, least squares; VI, vilanterol.](thoraxjnl-2013-203600f03){#THORAXJNL2013203600F3}

Self-reported rescue albuterol/salbutamol use increased over the 14 days preceding an exacerbation ([figure 4](#THORAXJNL2013203600F4){ref-type="fig"}).

![Mean self-reported daily rescue use (albuterol/salbutamol) 14 days before and after the onset of severe asthma exacerbation for patients who experienced ≥1 or 0 severe asthma exacerbations, intent-to-treat population. \*Date of onset was determined by the investigator and recorded in their clinical notes. For patients who experienced ≥1 severe asthma exacerbation, all severe asthma exacerbations are included in the figure. Rescue use in patients who did not exacerbate during the study was calculated for the same duration (number of days) as each exacerbation event in exacerbating patients. For this purpose, the surrogate Day 0 for non-exacerbators was the median study day of onset for all exacerbations. FF, fluticasone furoate; VI, vilanterol.](thoraxjnl-2013-203600f04){#THORAXJNL2013203600F4}

Adjusted mean changes from the baseline Asthma Control Questionnaire (ACQ7) are shown in online supplementary figure E6. Significantly greater improvements in the ACQ7 score were observed in patients receiving FF/VI compared with FF at all time points (p\<0.001; week 12, week 36 and endpoint). The proportion of patients with well-controlled asthma (ACQ7 score ≤0.75) at baseline was similar in the two treatment groups (both 2%). ORs for FF/VI versus FF at week 12 (1.49, 95% CI 1.20 to 1.84), week 36 (1.49, 95% CI 1.21 to 1.83) and at endpoint (1.50, 95% CI 1.23 to 1.82) indicated that patients in the FF/VI group were significantly more likely to be well controlled than those in the FF group (all p\<0.001). At endpoint, more patients in the FF/VI group than the FF group were well controlled (44% vs 36%).

Safety assessment {#s3c}
-----------------

Similar proportions of patients experienced severe asthma exacerbations leading to hospitalisation with FF (n=9, \<1%) and FF/VI (n=8, \<1%). In the FF group, 26 (3%) patients visited an emergency department or urgent care clinic due to a severe asthma exacerbation and 142 (14%) made unscheduled visits to a healthcare provider. These frequencies were 22 (2%) and 119 (12%), respectively, for FF/VI. No patients were intubated due to a severe asthma exacerbation.

FF and FF/VI had similar overall safety profiles ([table 3](#THORAXJNL2013203600TB3){ref-type="table"}). There were 29 (3%) on-treatment serious adverse events (SAEs) in the FF group (seven considered asthma-related by the adjudication committee) and 41 (4%) in the FF/VI group (10 considered asthma-related). Four on-treatment and post-treatment SAEs were deemed treatment-related, three (pleurisy, asthma, non-cardiac chest pain) in the FF group and one (tachyarrhythmia) in the FF/VI group. Three fatalities occurred: two (pneumonia, metastatic lung cancer (post-treatment)) in the FF group and one (automobile accident as passenger) in the FF/VI group; none were deemed to be treatment-related or asthma-related by the investigators or adjudication committee.

###### 

Most frequent (≥5%) on-treatment AEs, intent-to-treat population

  AE (preferred term)                 Number (%) of patients   
  ----------------------------------- ------------------------ ----------
  Any on-treatment AE                 652 (65)                 636 (63)
  Treatment-related AE\*              67 (7)                   69 (7)
  AE leading to withdrawal\*          19 (2)                   16 (2)
  Any on-treatment SAE                29 (3)                   41 (4)
  Treatment-related SAE\*             3 (\<1)                  1 (\<1)
  Asthma-related SAE                  7 (\<1)                  10 (\<1)
  Headache                            179 (18)                 188 (19)
  Nasopharyngitis                     131 (13)                 155 (15)
  Upper respiratory tract infection   93 (9)                   73 (7)
  Bronchitis                          74 (7)                   59 (6)
  Cough                               64 (6)                   55 (5)
  Oropharyngeal pain                  55 (5)                   41 (4)
  Influenza                           38 (4)                   50 (5)

\*On-treatment and post-treatment.

AE, adverse event; FF, fluticasone furoate; SAE, serious adverse event; VI, vilanterol.

Small but statistically significant treatment differences in change from baseline in diastolic blood pressure were observed at week 44 (--0.8 mm Hg, p=0.022) and week 76/end of study (--0.7 mm Hg, p=0.032); however, these were not considered to be clinically important. No statistically significant treatment differences in systolic blood pressure or pulse rate were observed.

Discussion {#s4}
==========

This study showed that, in patients with asthma uncontrolled on ICS, FF/VI 100/25 μg once daily administered for up to 78 weeks reduced the risk of experiencing a severe asthma exacerbation by 20% and reduced the rate of severe exacerbations per patient per year by 25% compared with FF 100 μg alone. FF/VI also significantly improved trough FEV~1~ and the number of patients achieving well-controlled asthma. FF/VI had a good safety profile without evidence of life-threatening asthma events. Reducing asthma exacerbations is considered in asthma guidelines to be the most important endpoint of future risk, and is of considerable benefit to patients because of their impact on quality of life and the high healthcare costs associated with their management. Although increasing the dose of ICS has been shown to be highly effective at reducing exacerbation risk, this approach needs to be considered in conjunction with the potential side effects of long-term use of higher doses of ICS.[@R20]

The results with FF/VI are consistent with those of many studies, confirming that the addition of a LABA to a medium dose of ICS improves lung function and asthma control and reduces the risk of severe asthma exacerbations including hospitalisations.[@R1] [@R21] However, our study is the first to demonstrate this improvement with once-daily dosing. We did not compare the efficacy of FF/VI treatment with doubling the dose of FF in this cohort of patients with uncontrolled asthma, but results from studies with that design have provided clear evidence of greater clinical benefit of combination therapy compared with doubling the dose of ICS.[@R24] Unlike FP and beclametasone dipropionate, for which three doses are available for use in adults, two doses of FF will be available for use in adults/adolescents. FF 100 μg is suitable for use in patients who require FP 100--250 μg twice daily and FF 200 μg is suitable for patients who require FP 500 μg twice daily or equivalent. Therefore, in this study, some patients will have been randomised to a similar ICS dose to baseline and some may have received a reduced ICS dose.

In this study the results of secondary endpoints, including annualised rate of severe exacerbations, further support the primary endpoint. The improvements in trough FEV~1~ and reductions in ACQ7 scores confirm superior current asthma control with the FF/VI combination. In addition, the frequency of severe asthma exacerbations leading to hospitalisation, emergency room visit or unscheduled healthcare provider visit was similar for both FF and FF/VI. Thus, there was no indication of an increased risk of such severe events with the addition of the LABA, a finding that is consistent with several meta-analyses of studies comparing combined ICS/LABA with ICS alone.[@R6] [@R7] [@R23]

Interpreting the clinical significance of exacerbation reductions in clinical trials is easiest when the comparator is usual treatment. In this study two new treatments were compared: a new once-daily moderate dose of FF and FF combined with VI. The resultant annualised rate of severe asthma exacerbations was low in both treatment groups, 0.19 for FF (corresponding to approximately one exacerbation every 5 years per patient) and 0.14 for FF/VI (one every 7 years), despite the fact that all patients were required to have had a severe asthma exacerbation during the 1-year period prior to randomisation. The exacerbation rate observed in the FF group compares favourably with those observed in previous studies of patients uncontrolled on medium-dose ICS, in which annualised rates ranging from 0.31 to 0.35 were reported for patients receiving budesonide alone.[@R25] [@R27] [@R28] In two recent studies of the effect of adding salmeterol to FP on asthma exacerbation rates,[@R29] [@R30] rates of 0.27--0.30 exacerbations/patient/year were reported for patients using FP monotherapy. Thus, the 25% decrease seen in this study represents a clinically useful improvement from an already very low base rate.

Regarding safety, FF and FF/VI were well tolerated and the incidence of treatment-related adverse events and all SAEs was low and similar across treatment groups. No clinically relevant treatment differences in vital signs or liver function parameters were observed. In view of the concerns regarding a possible link between LABA use and asthma-related hospitalisations and fatal events,[@R4] no association was observed in this study of \>2000 patients with a mean exposure of ≥12 months, although we recognise that this cannot be viewed as conclusive evidence.

The current ERS/ATS Task Force definition of severe asthma exacerbations[@R17] was used, and an adjudication committee provided a blinded review to ensure that all severe asthma exacerbations were identified and included in the primary measure. In addition, the monitoring of rescue use preceding and during the time of each severe asthma exacerbation confirmed that exacerbations were preceded by a period of loss of asthma control, supporting the accuracy and appropriateness of recording of asthma exacerbations.[@R31]

Strengths of this study include its innovative design in which the duration was not predetermined. Instead, the study was terminated when a specified number of acute exacerbations had occurred. In addition, most patients remained in the study and received treatment for 52 weeks or more, thus permitting a reliable determination of the annualised rate of severe asthma exacerbations. In contrast, in studies of fixed duration, although nominally of 12 months' duration, mean exposures to study drugs are reduced owing to premature withdrawals, particularly for patients who experience exacerbations. However, the event-driven design makes it difficult to compare the results of the present study with those of fixed duration. In our study, informative censoring did not occur differentially between the two treatment arms.

The dose of FF/VI (100/25 μg) used in this study was selected on the basis of data from earlier phase dose-ranging studies.[@R12] [@R13] [@R32] FF 100 μg was used as the comparator, ensuring that all patients were treated with at least a mid-strength ICS throughout the study. This study was not designed to compare the effect of adding a LABA with that of increasing the dose of ICS. The study did not examine the effect of time of dosing. Finally, the study population exhibited marked bronchodilator responsivenes to a β~2~ agonist (salbutamol) at the screening visit (approximately 500 mL and 22% of baseline), although only 200 mL and 12% was required for inclusion.

In summary, this study confirms that the combination of FF/VI 100/25 μg administered once daily in the evening to adolescents and adults with moderate asthma significantly reduced the risk of severe asthma exacerbations, improved lung function and led to asthma control in a larger proportion of patients than FF 100 μg. Both treatments were well tolerated with similar safety profiles and a low incidence of treatment-related AEs and SAEs, and no increased risk of serious asthma-related events was seen with the addition of VI.
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